Sanofi Pasteur Partners With Vivalis For The Discovery of Human Monoclonal Antibodies Against Infectious Diseases

10-Jun-2010 - France

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced the signature with Vivalis of a commercial license and collaboration agreement for the discovery and development of fully human monoclonal antibodies against several infectious diseases.

Under the terms of the agreement, Sanofi Pasteur and its affiliates acquire exclusive access to Vivalis’ platform for the discovery of fully human monoclonal antibodies targeting clinically significant infectious diseases, and will obtain worldwide exclusive development and commercialization rights for the discovered antibodies.

“Passive immunization can be a powerful treatment option against infectious diseases in sometimes life threatening situations. Vivalis’ Humalex® technology allows rapid identification of clinically relevant fully human antibodies, as well as their related antigen. This opens up new medical solutions to prevent or treat serious infections,” said Michel de Wilde, Senior Vice President, Research and Development, Sanofi Pasteur. “We are pleased to team up with Vivalis to discover and develop new biologicals against infectious diseases for patients worldwide.”

Vivalis will receive an upfront payment of 3 million euros, and may receive development milestone payments of up to 35 million euros over the course of the development of each infectious disease indication, as well as royalty payments associated with product sales. In addition, Sanofi Pasteur will finance agreed upon collaborative research activities related to the infectious diseases programs.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous